Beyond Weight Loss: What New GLP-1 Research Says About Heart, Kidney, Liver, Sleep and Breast Health

3 days ago

5 min read

Why researchers are looking beyond the scale

GLP-1 receptor agonists mimic a naturally occurring gut hormone involved in appetite, blood sugar and digestion. Some medicines also act on GIP, another metabolic hormone. The class includes different drugs with different approved uses, doses and evidence.

That distinction matters. A benefit shown with semaglutide in people who already have cardiovascular disease does not automatically apply to every GLP-1 medicine or every person. The same is true for kidney disease, sleep apnea, liver disease and cancer research.

The headline is promising. The responsible interpretation is specific: which drug, which people, which outcome and what kind of study?

20% relative reduction in major cardiovascular events in SELECT

24% lower risk of the primary kidney/cardiovascular composite in FLOW

Read percentages carefully. These are relative comparisons within specific trials, not a promise of individual benefit. Personal absolute risk can be very different.

Sources: SELECT and FLOW, New England Journal of Medicine (2023, 2024).

Heart and Kidney Outcomes

Heart: SELECT tested outcomes, not just weight

In the randomized SELECT trial, 17,604 adults had established cardiovascular disease and overweight or obesity, but not diabetes. Weekly semaglutide was associated with a 20% relative reduction in a composite of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo. This is meaningful outcome evidence, but it belongs to that high-risk population. It should not be restated as a universal 20% benefit for anyone taking any GLP-1 medication. The trial also found more treatment discontinuations because of adverse events with semaglutide, largely gastrointestinal symptoms.

Population check: adults age 45 or older with preexisting cardiovascular disease and BMI of 27 or higher, without diabetes.

Kidneys: FLOW focused on diabetes plus chronic kidney disease

In the randomized FLOW trial, 3,533 people with type 2 diabetes and chronic kidney disease received semaglutide or placebo. Semaglutide was associated with a 24% lower risk of the study's primary composite outcome, which included major kidney events and death from kidney or cardiovascular causes. Again, context is everything. FLOW does not show that every person using a GLP-1 medicine will receive the same kidney benefit. It tested semaglutide in people who already had both type 2 diabetes and chronic kidney disease.

Strong trials can support important treatment conversations while still requiring a clinician to match the evidence to the individual.

What to ask a clinician

Does the study population resemble my medical situation? Which outcome matters most for me: blood sugar, weight, cardiovascular risk, kidney risk or something else? What side effects, contraindications, interactions and follow-up should we review?

Sleep Apnea and Liver Disease in GLP-1 Research

Sleep: fewer breathing interruptions in SURMOUNT-OSA

SURMOUNT-OSA included adults with obesity and moderate-to-severe obstructive sleep apnea. Across two randomized trials, tirzepatide reduced apnea-hypopnea events by an estimated 20.0 and 23.8 events per hour more than placebo, depending on whether participants were also using positive airway pressure therapy. The most common adverse events were gastrointestinal and generally mild to moderate. Sleep apnea can carry serious health risks; prescribed therapies and follow-up should not be stopped because of a research headline.

Liver: a new approved use, with an important qualifier

In August 2025, the FDA granted accelerated approval to Wegovy (semaglutide) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced F2-F3 fibrosis. The current FDA label states that this indication was approved based on improvement in MASH and fibrosis.

Why "accelerated" matters: continued approval may depend on verification of clinical benefit in a confirmatory trial. This is not a general approval for every type of fatty liver disease.

Research correspondence in the New England Journal of Medicine also noted better MASH resolution and fibrosis regression with weekly semaglutide than placebo at 72 weeks, while emphasizing that substantial weight loss itself can improve liver histology.

Breast-cancer research: an observed signal, not proof

A retrospective study presented at the June 2026 American Society of Clinical Oncology meeting and published in JCO Oncology Practice examined electronic health records from 111,646 women ages 45 to 80 with BMI of 25 or higher who had breast imaging and a documented outcome.

Breast cancer was identified in 1.62% of women with documented GLP-1 exposure and 2.47% of women without exposure in the full cohort. After one-to-one matching for age, race, ethnicity, BMI, breast density and type 2 diabetes status, the odds ratio was 0.695 — approximately 30.5% lower odds in the GLP-1 group.

About the widely shared 30-47% figure: Medical Daily reported that women with type 2 diabetes or obesity who used GLP-1 medicines had a 30-47% lower breast-cancer risk and reported that the roughly 30% association remained after adjustment for BMI and weight change. The primary JCO paper supports the approximately 30% matched finding, but the excerpt reviewed describes matching for BMI and other characteristics — not a separate weight-change adjustment. For that reason, the 30-47% range and weight-change wording should be attributed specifically to Medical Daily.

Keep the breast-health finding in perspective

The study is encouraging because the lower incidence remained after researchers matched women on several major characteristics. But it was observational. It can identify an association; it cannot establish that GLP-1 treatment caused the lower breast-cancer incidence. The primary paper also notes limitations: the analysis did not account for the specific GLP-1 medicine or duration of use, genetic risk factors, or cancer stage and subtype. Researchers have called for prospective trials. GLP-1 medicines are not approved for breast-cancer prevention. This observed signal does not replace mammograms, MRI when indicated, genetic counseling or other recommended screening. Do not start, stop or change medication because of this finding without speaking with a licensed clinician. "Associated with" is not the same as "prevents."

Medical disclaimer

This article is for general education only and is not medical advice, diagnosis or treatment. GLP-1 medicines are prescription drugs with benefits, risks, contraindications and monitoring needs. Talk with a licensed healthcare professional who knows your history before making medication decisions. Keep up with recommended cancer screening and standard medical care.

A practical wellness conversation

The research points toward a broader metabolic-health story: in specific populations, specific GLP-1-based medicines have shown benefits or promising signals involving the heart, kidneys, sleep and liver, with breast health now under active investigation. The useful next step is not self-prescribing. It is bringing good questions to a qualified clinician: Which evidence applies to me? What are my goals and baseline risks? How will we monitor benefit, nutrition, muscle health and side effects? What standard care must continue?

Promising research is a reason for a better conversation — not a shortcut around individualized care.